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Our mucosal surfaces are the main sites of non-vector-borne pathogen entry, as well 
as the main interface with our commensal microbiota. We are still only beginning to 
understand how mucosal adaptive immunity interacts with commensal and pathogenic 
microbes to influence factors such as infectivity, phenotypic diversity, and within-host 
evolution. This is in part due to difficulties in generating specific mucosal adaptive 
immune responses without disrupting the mucosal microbial ecosystem itself. Here, 
we present a very simple tool to generate inactivated mucosal vaccines from a broad 
range of culturable bacteria. Oral gavage of 1010 peracetic acid-inactivated bacteria 
induces high-titer-specific intestinal IgA in the absence of any measurable inflammation 
or species invasion. As a proof of principle, we demonstrate that this technique is suffi-
cient to provide fully protective immunity in the murine model of invasive non-typhoidal 
Salmonellosis, even in the face of severe innate immune deficiency.
Keywords: oral vaccines, inactivated vaccines, Salmonella typhimurium, Yersina enterocolytica, iga
inTrODUcTiOn
Many immune mechanisms controlling bacterial infection in the blood and systemic secondary 
lymphoid organs are well described and understood (1, 2). As the systemic immune system is exqui-
sitely sensitive to bacterial-derived “pathogen-associated molecular patterns” (PAMPs) and antigens, 
parenteral introduction of very low concentrations of live or inactivated bacteria induces high titer 
serum IgG responses and T cell activation in experimental animals (3). These simple vaccination 
protocols have permitted the elucidation of major effector functions, including antibody-mediated 
enhancement of phagocytosis and pathogen recognition (2), T cell help to orchestrate appropriate 
cell-mediated antimicrobial responses (4, 5), and enhancement of the microbicidal activity of the 
complement system (1). Correspondingly, we have been able to identify a large number of mecha-
nisms by which bacterial pathogens subvert and evade systemic immunity and can start to apply this 
knowledge clinically (6).
By contrast, our knowledge of immune effector function at mucosal surfaces, particularly in the 
intestinal system, remains incomplete (7, 8). The mammalian large intestine is home to an extraor-
dinarily dense microbial consortium, known as the microbiota. Among other functions, these 
microorganisms determine the host nutrient profile (9), densely occupy intestinal niches providing 
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“colonization resistance” to infection (10), and determine the 
immune status of the host (11). Coevolution has produced an 
intestinal immune system that is both compartmentalized away 
from the systemic system such that parenteral immunization does 
not induce robust mucosal immunity (12) and rather insensitive 
to locally delivered bacterial PAMPs and antigens in order to 
coexist with the commensal microbiota (11, 13). In comparison 
to activation of systemic immunity, it is therefore a considerable 
challenge to activate the intestinal immune system, in particular 
to induce high-affinity secretory IgA, the major antibody isotype 
secreted into the intestinal lumen.
In order to induce strong intestinal immunity, it is necessary 
to deliver both antigen and appropriate adjuvant-derived signals 
into the gut-associated lymphoid tissues [recently reviewed 
in Ref. (14)]. The most potent strategies to induce bacteria-
specific IgA employ live-attenuated invasive pathogens [e.g., 
Salmonella enterica ssp. enterica ser. Typhimurium (15), Shigella 
species (16)]. This had led to the suggestion that some degree of 
pathogenicity, such as the ability to invade into the epithelium or 
subvert phagocyte function, is required for induction of intestinal 
immunity (17–21). While mucosal adaptive immunity can easily 
be activated by these vaccines, the vaccination process itself is 
often associated with mild inflammation, persistent colonization 
of secondary lymphoid tissues, and shifts in microbiota composi-
tion, due either to live vaccine presence or inflammatory processes 
(18, 22, 23). Any major perturbation of the microbiota has the 
potential to modify a very broad spectrum of host physiological 
functions (11), necessarily complicating the dissection of effector 
mechanisms. Furthermore, it is difficult and generally undesirable 
to generate an invasive pathogen from an apathogenic species in 
order to study immunity in host–commensal interactions.
An alternative strategy employed by us and others, particularly 
in the study of commensal microbes, is the gavage of high num-
bers of live apathogenic bacteria (24–27). For example, specific 
IgA is induced by six oral doses of 1010 live Escherichia coli K-12, 
which is a lab-adapted strain free of any identifiable virulence 
mechanisms (13). This effect can be mimicked by monocoloniz-
ing germ-free mice with very low numbers of apathogenic bac-
teria, providing those bacteria grow up to a high density in the 
otherwise uncolonized intestinal lumen (13, 25). Therefore, 
pathogenicity is not absolutely necessary for induction of specific 
IgA responses if high loads of live bacteria are present. Again, 
the drawback of this method for IgA induction is that the animal 
tends to be permanently colonized with the vaccination strain 
from the initiation of vaccination (24–27). This makes it very dif-
ficult to clearly dissect effects on phenotype, colonization levels, 
etc. due to niche occupancy and shifts in host physiology. Elegant 
work with auxotrophic mutations can generate systems where the 
vaccination strain does not permanently colonize a  germ-free 
mouse, permitting later re-challenge and study (13, 28). However, 
this requires powerful genetic systems in your organism of choice 
as well as a very detailed knowledge of bacterial metabolism and 
potential escape mechanisms.
The use of fully inactivated oral vaccines is, therefore, highly 
attractive as there is potential to induce a specific mucosal 
immune response without inducing inflammation and without 
persistently colonizing the intestine and/or associated lymphoid 
tissues. In the murine system, inactivated oral vaccines have often 
been found to be ignored by the mucosal immune system (13, 27). 
However, inactivated oral vaccines are so far the most successful 
strategy to induce at least partially protective immunity against 
enteric bacterial pathogens in humans (29). The human cholera 
vaccines Shanchol® and Dukoral® rely on oral delivery of more 
than 1010 inactivated Vibrio cholerae in the presence or absence of 
the mucosal adjuvant recombinant cholera toxin B subunit (30). 
An enterotoxigenic E. coli vaccine currently in clinical trials (31) 
is also based on oral delivery of inactivated bacteria along with the 
heat-labile toxin, a homolog of cholera toxin with known mucosal 
adjuvant activity. An inactivated Shigella flexneri vaccine is also 
showing promise in humans (32). It is, therefore, clear that suc-
cessful oral vaccination of humans can be achieved in the absence 
of live bacteria; at least if a known mucosal adjuvant is present.
It is unclear why this discrepancy exists in the dogma between 
human and murine oral vaccination. Nevertheless, mouse infec-
tion/colonization remains the most commonly used system to 
elucidate biological mechanisms of host–microbe interactions, as 
experiments can be carried out that are simply not possible in 
human patients. We hypothesized that previous failure of inacti-
vated oral vaccines in murine systems may be due to quantitatively 
insufficient delivery of antigens and PAMPs. Our previous work 
had determined that both the dose and the particulate nature of the 
vaccine were important to induce specific IgA (13). Therefore, in 
order to produce oral vaccines at concentrations of more than 1010 
inactivated bacteria per 100 μl dose, we needed a drastic inactiva-
tion method that nevertheless minimized bacterial lysis. To this 
end, we made use of the very strong oxidizing agent peracetic acid 
(33–35). We were able to fully inactivate a taxonomically diverse 
range of bacterial species to generate particulate oral vaccines. As 
a proof of principle, we here demonstrate induction of high-titer 
IgA responses against a range of Enterobacteriaceae species.
In order to compare this strategy to existing oral vaccines, 
we made use of the murine model of invasive non-typhoidal 
Salmonellosis (36). This is a particularly challenging model for 
vaccination-mediated protection as <10  CFU delivered orally 
results in lethal infection within 5 days (36), and live-attenuated 
vaccine strains are known to cause severe pathology in mice 
with innate immune deficiencies (37). Using our peracetic acid-
inactivated S. Typhimurium vaccine, we could generate high-titer 
IgA in the absence of any detectable intestinal pathology, and 
could observe sterile protection from disease, even in the mouse 
model of chronic granulomatous disease.
MaTerials anD MeThODs
ethics statement
All animal experiments were approved by the legal authorities 
(licenses 223/2010 and 222/2013; Kantonales Veterinäramt 
Zürich, Switzerland) and performed according to the legal and 
ethical requirements.
Mice
SOPF C57BL/6, JH−/− (38), cybb−/− (39), IgA−/− (40), and TCRβδ−/− 
(41) mice (all C57BL/6 background) were re-derived by artificial 
TaBle 1 | Bacterial strains used in this study.
species name strain 
name
genetic 
modifications/
resistances
source
Salmonella enterica 
serovar Typhimurium
SB300 None Murine passage of the 
type-strain SL1344 (44)Streptomycin 
resistant
Salmonella enterica 
serovar Typhimurium
M2702  ΔsseD::ΔinvG SB300 derivative (50)
Streptomycin 
resistant
Salmonella enterica 
serovar Typhimurium
M556 sseD::aphT SB300 derivative (50)
Streptomycin 
resistant
Kanamycin 
resistant
Salmonella enterica 
serovar Typhimurium
SKI10 wbaP::aphT SB300 derivative (50)
Streptomycin 
resistant
Kanamycin 
resistant
Salmonella enterica 
serovar Enteritidis
125109 Wild type (62)
Salmonella enterica 
serovar Choleraesuis
ATCC25957 
(914/99) 
Wild type (63)
Citrobacter rodentium DSM 16636 Wild type (64)
Yersinia enterocolitica JB580 Wild type Kind gift from Prof. 
Markus Aebi, ETH 
Zurich (65)
Klebsiella pneumonia Human fecal 
isolate
(66)
E. coli Nissle 1914 Human isolate (67)
E. coli 8178 Mouse 
commensal 
isolate
(23)
Burkholderia 
multivorans
AE1064722 Cystic fibrosis 
patient lung 
isolate
Kind gift of Dr. A. 
Endimiani, University 
of Bern 
Moraxella catarrhalis O35E Human isolate (68)
Staphylococcus 
aureus
NCTC 8532 Human lung 
isolate
ATCC
Staphylococcus 
epidermidis
Human skin 
isolate
(69)
Staphylococcus 
xylosus
Mouse fecal 
isolate
(45)
Enterococcus faecalis Mouse fecal 
isolate
(45)
Enterococcus faecalis Human fecal 
isolate
(69)
Pseudomonas 
aeruginosa
PA01 Wild-type strain Institute strain collection
Pseudomonas 
fluorescens
Institute strain collection
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insemination into a specific opportunistic pathogen-free (SOPF) 
foster colony to normalize the microbiota and bred in full barrier 
conditions in individually ventilated cages in the ETH Phenomics 
center (EPIC), ETH Zürich, for <4 generations. Specific 
pathogen-free mice (SPF) wild-type C57BL/6 mice were bred at 
the Rodent center HCI (RCHCI), ETH Zürich, in individually 
ventilated cages. Low complex microbiota (LCM) mice (C57BL/6 
background) are ex-germ-free mice, which were colonized with 
a naturally diversified Altered Schaedler flora in 2007 (23) and 
were bred in individually ventilated cages under strict hygienic 
isolation at the RCHCI ETH Zürich. All mice were used between 
6 and 12  weeks of age. Wherever possible, male and female 
mice were randomized between groups to permit detection of a 
gender-specific effect.
Bacterial strains and growth conditions
For infection experiments, the streptomycin-resistant wild-type 
strain S. enterica serovar Typhimurium (SL1344 wild-type clone 
SB300) or the isogenic sseD::aphT SPI2 mutant S. Typhimurium 
(M556) [described previously in Ref. (42, 43)] were cultured in LB 
for 12 h at 37°C and subcultured for 3 h as described previously 
(44). For vaccine production and antibody titering, all strains 
(Table 1) were cultured overnight in LB medium with aeration 
to late stationary phase.
Testing of (a) Paraformaldehyde Fixation, 
(b) Mild heat-Treatment, and (c) hydrogen 
Peroxide-Mediated Vaccine inactivation
One liter of LB was inoculated with avirulent S. Typhimurium 
and cultured overnight at 37°C with shaking. The bacteria were 
concentrated by centrifugation at 16,000  ×  g for 20  min and 
resuspended in 10  ml D-PBS without Calcium or Magnesium 
(e.g., 14190-094, Gibco, Waltham, MA, USA). The 500 μl aliquots 
were then made in 2  ml snap-cap tubes (Sarstedt, Nümbrecht, 
Germany). Three aliquots were subjected to the following treat-
ments: (A) heat-treatment (1 h, 60°C with mild agitation in an 
Eppendorf Thermomixer); (B) PFA fixation [the bacteria were 
pelleted by centrifugation at 16,000 × g and resuspended in 1 ml 
of 4% paraformaldehyde (158127, Sigma-Aldrich, St. Louis, MO, 
USA) in D-PBS and incubated for 1 h at room temperature (RT)]; 
or (C) H2O2 inactivation [the bacteria were transferred to a 50 ml 
tube to contain the effervescence and 30% H2O2 (H-1009, Sigma-
Aldrich) was added to a final concentration of 3%. The suspension 
was incubated for 1 h at RT]. This was compared to peracetic acid 
mediated inactivation on matched aliquots, as described in the 
paragraph below. After 1 h, the cultures, along with a control sam-
ple in PBS only at RT, were washed three times with 1 ml D-PBS to 
remove inactivating agents and were then resuspended in 500 μl 
for analysis. The 100 μl per sample were inoculated into 200 ml LB 
for overnight culture to determine sterility. The remaining sample 
was used for bright-field microscopy and FACS counting.
Production of Peracetic acid-inactivated 
Vaccines
Bacteria for peracetic acid-inactivated vaccines were grown 
overnight to late stationary phase at their respective optimal 
growth conditions. Bacteria were harvested by centrifugation 
(16,000 × g, 15 min) and resuspended at a density of 109–1010 per 
ml in sterile D-PBS. The 10 ml aliquots were transferred to sterile 
50-ml Falcon tubes. Peracetic acid (433241, Sigma-Aldrich) 
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was added to a final concentration of 0.4%. The suspension was 
mixed thoroughly and incubated for 1 h at RT. The bacteria were 
washed three times in 50 ml sterile D-PBS, meticulously remov-
ing all supernatant after each centrifugation step, and thoroughly 
resuspending the pellet each time to rapidly remove the peracetic 
acid. The final pellet was resuspended at a final concentration of 
1011 particles per ml in sterile D-PBS (determined by OD600) and 
stored at 4°C for up to 3 weeks. As a quality control, each batch of 
vaccine was tested before use by inoculating 100 μl of the inacti-
vated vaccine (one vaccine dose) into 200 ml LB and incubating 
over night at 37°C with aeration to ensure complete inactivation, 
i.e., a “negative enrichment culture.” One microliter of vaccine 
suspended in 100 μl D-PBS was used for bright-field microscopy. 
If aggregation was observed, the vaccine was aliquoted into sterile 
2-ml tubes (Sarstedt) each with a single sterile 5-mm steal ball 
[5 mm G80 1.3541, PO8(xq + 8) × B2 beads, Berani Kugellager 
AG, Uster, Switzerland]. The tubes were then shaken at 25  Hz 
for 1 min in a Retsch Tissuelyser (Qiagen, Hilden, Germany) to 
disrupt aggregates.
Facs Quantification of intact inactivated 
Bacterial Particles
In order to quantify the total intact bacterial particles, the OD600 
of prepared vaccines or control live bacterial suspensions was 
measured. The suspensions were then diluted to give an approxi-
mate OD600 of 0.1 and the dilution factor noted. The 150 μl of 
this culture was then added to 150 μl of PBS containing and 
known concentration of Fluoresbrite Multifluorescent 1  μm 
Microspheres (Polysciences, Warrington, PA, USA) (in the range 
of 108 per ml, which is roughly 50 μl of the delivered bead suspen-
sion in 10 ml PBS, as determined by dilution and hemocytometer 
counting). Samples were acquired on an LSRII Flow cytometer 
(Becton Dickenson, NJ, USA) with forward- and side-scatter 
parameters in logarithmic mode and both parameters thresh-
olded on a low value to exclude electronic noise but detect beads 
and bacteria. Beads were identified based on a “beads only” 
sample, as highly fluorescent in all channels. Bacteria/vaccine 
were identified by the absence of fluorescence as compared to the 
“bead-only” sample. Ten thousand multifluorescent bead events 
were acquired for each sample and the “counts” of beads and 
bacteria extracted by analysis in FlowJo (Treestar, Ashland, OR, 
USA). The background in the bacterial gate acquired with the 
“beads-only” sample was subtracted from all bacterial counts. 
The concentration of bacteria was then calculated using the 
formula Bacterial density = Bead density*bacteria FACS counts/
Beads FACS counts.
Oral Vaccination with Peracetic  
acid-inactivated Vaccines
Mice received 1010 particles of the respective peracetic acid-inac-
tivated bacteria in 100 μl of D-PBS by oral gavage once per week 
for 3 weeks. Except where stated in Figure 4, no antibiotics were 
applied during the vaccination period. Unless otherwise stated, on 
day 21 after the first gavage (i.e., 7 days after the final gavage), mice 
were used for analysis of antibody titers or infection experiments. 
For the data show in Figure 4C, mice received 0.8 g/kg ampicillin 
sodium salt (A0839, Applichem, Darmstadt, Germany) in sterile 
water or 1.0 g/kg gentamicin sulfate (A1104, Applichem) in sterile 
water by gavage 24 h prior to each dose of vaccine.
Oral Vaccination with live-attenuated 
Salmonella
Mice were pretreated with 1 g/kg streptomycin sulfate (A1852, 
AppliChem) in sterile water by gavage. Twenty-four hours 
later, the mice were inoculated with 5 × 107 CFU avirulent S. 
Typhimurium sseD::aphT (M556) by gavage [as described in 
Ref. (18)].
analysis of specific antibody Titers by 
Bacterial Flow cytometry
Specific antibody titers were analyzed in mouse serum and 
intestinal washes by flow cytometry as described previously (45). 
Briefly, intestinal washes were collected by flushing the small 
intestine with 5 ml of a wash buffer containing PBS, 0.05M EDTA 
(A1104, Applichem), and 1  μg/ml Soybean trypsin inhibitor 
(T9128, Sigma-Aldrich). Intestinal washes were centrifuged at 
16,000 × g for 30 min and aliquots of the supernatants were stored 
at −20°C until analysis. Blood was collected into tubes contain-
ing clotting activating gel (41.1395.005, Sarstedt) and allowed 
to clot at RT for 30 min before centrifugation at 16,000 × g for 
15 min. Bacterial targets (antigen against which antibodies are 
to be titered) were grown to late stationary phase and gently 
pelleted for 2  min at 3000 ×  g in an Eppendorf minifuge. The 
pellet was washed with sterile-filtered FACS buffer [PBS, 1% 
Bovine serum albumin factor V (K41-001, GE Healthcare, Little 
Chalfront, UK), 0.05% sodium azide (71289, Sigma-Aldrich)] 
before resuspending at a density of approximately 107 bacteria 
per ml. Intestinal washes and serum were heat-inactivated for 
30 min at 56°C and centrifuged again at 16,000 g for 10 min to 
remove bacterial sized particles that may have been generated 
by the heat-treatment. Supernatants were used to perform serial 
dilutions. The 25 μl of the dilutions were incubated with 25 μl 
bacterial suspension at 4°C for 1 h. Bacteria were washed twice 
with 200 μl FACS buffer before resuspending in the appropriate 
antibody cocktail: monoclonal FITC-anti-mouse IgA (10 μg/ml, 
559354, Clone C10-3, BD Pharmingen, New Jersey, NY, USA), 
FITC-anti-mouse IgG2b (5  μg/ml, 406706, Clone RMG2b-
1, BioLegend, San Diego, CA, USA), PE-anti-mouse IgG1 
(5 μg/ml, 406608, Clone RMG1-1, BioLegend), and APC/Cy7-
anti-mouse IgM (5 μg/ml, 406516, Clone RMM-1, BioLegend). 
After 1 h of incubation, bacteria were washed once with FACS 
buffer and resuspended in 300  μl FACS buffer for acquisition 
on FACS LSRII using FSC and SSC parameters in logarithmic 
mode. Data were analyzed using FlowJo (Treestar, Ashland, OR, 
USA). After gating on bacterial particles and compensation for 
bleed-through between fluorescence detectors where appropri-
ate, median fluorescence intensities (MFI) were plotted against 
antibody concentrations for each sample and 4-parameter logistic 
curves fitted using Prism (Graphpad, La Jolla, CA, USA). Titers 
were calculated from these curves as the inverse of the antibody 
concentration giving an above-background signal (see Figure S1 
in Supplementary Material).
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challenge of Vaccinated animals with 
Wild-Type S. Typhimurium
Salmonella infections were performed in individually ventilated 
cages at the RCHCI, Zurich as described previously (44). Mice 
were pretreated with 1  g/kg streptomycin sulfate (Applichem) 
in sterile PBS by gavage. Twenty-four hours later, the mice were 
inoculated with 5 × 105 CFU S. Typhimurium SB300 by gavage. 
As mentioned earlier, 24-h post infection, blood and intestinal 
lavages were collected for analysis of specific antibody titers. 
Bacterial loads (CFU) in fresh fecal pellets, mesenteric lymph 
nodes (mLN), spleen, and cecal content (CC) were determined 
by plating on MacConkey agar plates containing 50 μg/ml strep-
tomycin sulfate (Applichem).
histopathological evaluation
Samples of cecal tissue were embedded in OCT (Sakura, 
Torrqance, CA, USA) and snap frozen in liquid nitrogen. Five-
micrometer cross-sectional tissue sections were cut and stained 
with haemotoxylin and eosin [as described in Ref. (44)]. Tissue 
sections were scored for cecal pathology as described (44). Briefly, 
the cecum pathology score is based on edema, polymorphonuclear 
cell infiltration, reduced numbers of goblet cells, and epithelium 
disruption with a maximum score of 14.
elisas
Lipocalin 2 was detected in feces homogenized in 500 μl sterile 
PBS by ELISA using the DuoSet Lipocalin ELISA kit (DY1857, 
R&D Systems, Minneapolis, MN, USA) according to the 
manufacturer’s instructions. Total concentrations of antibody 
isotypes in mouse serum or intestinal lavages were determined by 
sandwich ELISA. Coating antibodies were goat anti-mouse IgA 
(1040-01, SouthernBiotec, Birmingham, AL, USA), goat-anti-
mouse IgG2b (1090-01, SouthernBiotec), goat-anti-mouse IgG1 
(1070-01, SouthernBiotec), and goat-anti-mouse IgM (1020-01, 
SouthernBiotec). Detection antibodies were HRP-conjugated 
anti-mouse IgA α chain (A4789, Sigma-Aldrich), anti-mouse IgG 
γ chain (A3673, Sigma-Aldrich), and anti-mouse IgM μ chain 
(A8786, Sigma-Aldrich). Standards were purified mouse IgA 
(03101D, Pharmingen) or mouse reference serum (RS10-101, 
Bethyl, Montgomery, TX, USA).
statistics
As we were predominantly working with datasets with N < 10, 
non-parametric tests were employed wherever possible. Where 
two groups of data are compared, analysis was carried out using 
two-tailed Mann–Whitney U tests with a significance cut-off 
of 5%. Where more than two groups were compared, data were 
analyzed by Kruskal–Wallis test with Dunns post-test to account 
for multiple testing. Where more than one variable was tested 
simultaneously, log-normally distributed data were normalized 
and tested by two-way ANOVA with Bonferroni post-tests. All 
statistics were evaluated using Graphpad Prism. The dendrogram 
was generated by multiple alignment of 16S rDNA sequences using 
ClustalX and NJPlot (Conway Institute UCD Dublin, Ireland). As 
very large effects with minimal variation were measured, power 
calculations were not necessary to determine sample size and we 
adhered to standard practice of analyzing at least five mice per 
group, wherever possible.
resUlTs
In order to deliver 1010 inactivated bacteria orally with a 
minimal risk of accidental infection, it was essential to have 
a method that very efficiently kills bacteria at high densities 
without destroying antigenic structures. To this end, we tested 
several different standard inactivation procedures, includ-
ing paraformaldehyde fixation (32), pasteurization (30), and 
hydrogen peroxide treatment (46), as well as a novel peracetic 
acid treatment, on the broad host-range pathogen S. enterica 
serovar Typhimurium (S. Typhimurium). As with many enteric 
pathogens, virulent S. Typhimurium carries a number of super 
oxide dismutase (SOD) genes (47, 48), and correspondingly 3% 
hydrogen peroxide treatment resulted in considerable gaseous 
oxygen production but very little toxicity (Figures  1A,B). As 
expected, 4% paraformaldehyde treatment and pasteurization 
for 1 h result in a 4–6log decrease in viable bacteria, but both 
methods are insufficient for the 10–11log decrease that we are 
aiming for (Figures 1A,B). 0.4% peracetic acid, presumably due 
to the combination of low pH and very strong oxidizing activ-
ity, cannot be fully inactivated by SOD enzymes. This treatment 
results in very minimal gas production and inactivates 1010 CFU 
S. Typhimurium to sterility, as determined by plating or enrich-
ment culture (Figures 1A,B). Very little lysis of S. Typhimurium 
was observed with any of the procedures tested (Figure  1C). 
Light microscopy revealed largely intact bacterial bodies after 
inactivation (Figure  1D). Sytox-green uptake, determined by 
microscopy (Figure 1D) or flow cytometry (data not shown), 
revealed uniform loss of membrane integrity in the peracetic 
acid-inactivated bacteria.
To demonstrate that the efficiency of peracetic acid treat-
ment was really sufficient for our needs, we used streptomycin 
pre-treated mice carrying a low-complexity microbiota, which 
are extremely sensitive to oral infection with streptomycin-
resistant Salmonella (49). Twenty four hours after streptomycin 
treatment, these mice received just 10 or 100 CFU of live wild-
type S. Typhimurium [strain SB300 (44)] or 5 × 1010 particles 
of peracetic acid-inactivated wild-type (SB300) or avirulent 
[ΔsseD ΔinvG (50)] S. Typhimurium. Three days post-gavage, all 
mice receiving live S. Typhimurium, but 0/10 mice gavaged with 
peracetic acid-inactivated bacteria had full-blown cecal inflam-
mation (Figures 1E,F) and high counts of S. Typhimurium in 
the intestinal content and mLN (Figures 1G,H). Thus, incuba-
tion in 0.4% peracetic acid is sufficient to kill >99.9999999% of 
all bacteria, preventing any pathological sequelae even when 
fully virulent wild-type S. Typhimurium was used as the vac-
cination strain.
In order to demonstrate that this process is applicable 
across a range of bacterial species, we aerobically cultured 17 
different pathogenic and commensal bacterial species from 
the Proteobacteria and Firmicutes phyla and examined their 
inactivation by peracetic acid (Figure  2A). Full inactivation of 
dense bacterial suspensions was observed for all species tested. 
FigUre 1 | Peracetic acid highly efficiently kills bacteria, with minimal lysis. (a–D) Avirulent S. Typhimurium was cultured overnight to stationary phase, 
concentrated, and inactivated by incubating in 3% H2O2 for 1 h, heating to 60°C for 1 h, incubating in 4% PFA/PBS for 1 h, or incubating in 0.4% peracetic acid for 
1 h. All aliquots were subsequently washed three times to remove fixatives/oxidizing agents before resuspending for CFU analysis by plating (a) and total sterility by 
enrichment culture (B). Lysis was determined by counting bacterial particles by flow cytometry (c). To examine morphology, the bacteria were diluted in PBS 
containing 0.5 μM Sytox-green and were imaged by bright-field and fluorescence microscopy at 100× magnification (D). One representative experiment of two. 
(e–h) C57BL/6 LCM mice received 1.0 g/kg streptomycin p.o. 24 h before oral gavage of 5 × 1010 particles of peracetic acid-inactivated wild-type S. Typhimurium 
SB300 (PA-wild-type), 5 × 1010 particles of peracetic acid-inactivated avirulent S. Typhimurium M2702 (PA-avirulent), or 10 CFU or 100 CFU of wild-type live S. 
Typhimurium SB300. After 72 h, all animals were analyzed. (e,F) Intestinal pathology as determined by histopathology or fecal Lipocalin 2 (LCN2). Kruskal–Wallis 
test, P = 0.0023 (g,h). Cecal content (Kruskal–Wallis test, P = 0.0007) and mesenteric lymph node CFU (Kruskal–Wallis test, P = 0.0007). **Dunn’s post-test, 
P < 0.01. One experiment with three to five mice per group.
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Spontaneous lysis in 0.4% peracetic acid was observed in only 
one species tested (Moraxella catarrhalis). Staphylococci and 
Enterococci tended to aggregate during inactivation, which 
is likely to inhibit sampling by the mucosal immune system. 
However, these aggregates could be easily disrupted by physi-
cal force, for example, vigorous shaking with a large steel bead 
(Figure  2B). The basic protocol we suggest (see Materials and 
Methods) is, therefore, a 1  h treatment of bacteria suspended 
at 1010 particles per ml in Dulbecco’s PBS (D-PBS) with 0.4% 
peracetic acid. After extensive washing with sterile D-PBS, a 
small aliquot of bacteria should be examined by standard light 
microscopy techniques to determine the extent of aggregation 
(or lysis if this is not macroscopically obvious). If aggregates are 
present, the vaccine can be homogenized by shaking at 25  Hz 
in the presence of a large sterile steel bead. The final vaccine 
preparation is resuspended with at least 1010 particles per 100 μl 
and a full 100 μl is taken into 200 ml appropriate sterile media 
for overnight culture to determine absolute sterility (Schematic 
diagram, Figure 2B). During this time, produced vaccine can be 
safely stored at 4°C. This is a broadly applicable, highly efficient 
bacterial inactivation technique that permits working with highly 
concentrated bacterial slurries in situations where administration 
of very few live bacteria would be confounding. A useful side-
observation from our work is that in the case of vaccine made 
from S. Typhimurium, the inactivated bacteria could be stored as 
a dense slurry in PBS at 4°C for at least 3 weeks.
We next compared the induction of specific intestinal IgA 
by orally delivered peracetic acid-inactivated bacteria and a 
standard live-attenuated Salmonella vaccine strain sseD::aphT 
(18, 50). When C57BL/6 mice were pre-treated with high-dose 
streptomycin and then infected with S. Typhimurium sseD::aphT 
(50), they developed a self-limiting intestinal inflammation and 
robust S. Typhimurium-specific intestinal immunity. In paral-
lel, we constructed a peracetic acid-inactivated vaccine from a 
fully avirulent S. Typhimurium mutant, henceforth, referred to 
as PA-STm (ΔsseD ΔinvG  –  M2702, used to minimize opera-
tor risk during vaccine preparation). 1010 particles of PA-STm 
were gavaged once per week for 3  weeks without antibiotic 
pre-treatment. On day 21 after the vaccination start, PA-STm-
treated mice developed a S. Typhimurium-specific intestinal IgA 
titer that is equivalent to that observed at 3 weeks post-infection 
with the live attenuated strain S. Typhimurium M556, as deter-
mined by bacterial flow cytometry (45) (Figures  3A,B; Figure 
S1 in Supplementary Material). Serum IgA and IgM responses 
were also equivalent between the two treatments (Figure S2 in 
Supplementary Material). Serum IgG2b (Figure  3C) and IgG1 
(Figure S2 in Supplementary Material) responses induced by 
PA-STm are low, but higher than those observed at the same 
time-point during infection with the live-attenuated vaccine. 
Mice receiving PA-STm displayed zero detectable intestinal 
inflammation as determined by histopathology scoring (data 
not shown), or by quantification of fecal Lipocalin 2 (Figure 3D) 
FigUre 2 | Peracetic acid can be used to inactivate a broad range of bacterial species relevant to intestinal immunology research. (a) Dendrogram 
based on 16S rDNA sequence differences of the species tested so far, highlighting potential pitfalls. Legend refers to the distance score as calculated by ClustalX 
neighbor-joining multiple alignment. (B) Schematic diagram of oral vaccine production, including homogenization to disrupt bacterial clumps produced during 
inactivation, and expected brightfield images.
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(51). Furthermore, no live S. Typhimurium was recovered from 
the cecum content or from draining lymphoid tissues of mice 
receiving high-dose peracetic acid-inactivated bacteria, whereas 
this is observed in 100% of mice vaccinated with live-attenuated 
strains at this time-point (Figures 3E,F). To demonstrate that this 
robust induction of specific IgA is not restricted to Salmonella 
Typhimurium, we tested peracetic acid-inactivated oral vaccines 
from a range of Enterobacteriaceae species in  vivo. We could 
demonstrate robust induction of specific IgA against two other 
non-typhoidal Salmonella serovars (Enteritidis  –  Figure  3G, 
Choleraesuis  –  data not shown), as well as the more distantly 
related species Yersinia enterocolitica and Citrobacter rodentium 
(Figures 3H,I).
We next tested the host requirements for induction of specific 
IgA by peracetic acid-inactivated Salmonella. As expected for 
a high-affinity antibody responses (52), induction of high-titer 
IgA by PA-STm was abroaged in TCRβ−/− TCRδ−/− mice (lacking 
the entire T cell compartment), even when lower total IgA pro-
duction was taken into account, indicating that the inactivated 
vaccine is also capable of eliciting a T follicular helper response 
facilitating specific IgA production (Figure  4A). Importantly, 
we observed a strong quantitative effect of different microbiota 
compositions on S. Typhimurium-specific IgA titers, which 
roughly correlated with hygiene status (Figure 4B). Mice with a 
very limited microbiota “LCM – low complexity microbiota” (23) 
(LCM – separate cages, Figure 4B), or mice recently re-derived 
into an ultra-clean SOPF foster colony (Figure  3A), produce 
very high IgA titers with little mouse-to-mouse variation. By 
contrast, mice bred in a SPF colony that harbors a more diverse 
microbiota, including low levels of protozoa (SPF  –  separate 
FigUre 3 | Oral Pa-sTm is a strong inducer of specific intestinal iga in the absence of pathology. C57BL/6 SOPF mice were either pre-treated with  
1.0 g/kg streptomycin and infected orally with 5 × 107 CFU of the oral vaccination S. Typhimurium strain M556 (SB300 ΔsseD) (“live”) or were gavaged once a week 
with 1010 particles of peracetic acid-killed S. Typhimurium (“PA-STm”) over 3 weeks. (a) Intestinal lavage IgA titer curves and (B) intestinal lavage IgA titers, as 
calculated in Figure S3 in Supplementary Material (Kruskal–Wallis test on log-normalized values, P < 0.0001, Pairwise comparisons calculated by Dunn’s post-tests). 
(c) Serum IgG2b titer curves at day 21 after the first vaccination/infection, as determined by bacterial flow cytometry. (D) Lipocalin 2 in feces at day 21 after the first 
vaccination/infection (Kruskal–Wallis test, P = 0.0054 with Dunn’s post-test). (e,F) CFU of live S. Typhimurium recovered from the cecal content and mesenteric lymph 
nodes at the same time-point. One representative experiment of two shown. (g–i) Specific IgA induced by vaccination with peracetic acid-killed vaccines generated 
from with S. Enteritidis, Yersinia enterocolitica, and Citrobacter rodentium. Titers were determined by flow cytometry and ELISA. N = 5 mice per vaccine tested.
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cages, Figure  4B), produced lower and more variable IgA 
titers specific for S. Typhimurium when vaccinated in paral-
lel. Cohousing of LCM mice with animals with a diverse SPF 
microbiota for 3 weeks prior to commencement of vaccination 
significantly decreased the titer of S. Typhimurium-specific IgA 
produced (co-housed, Figure 4B). Correspondingly, pre-treat-
ment of SPF animals with ampicillin or gentamicin 24 h prior 
to each vaccination increased final antibody titers (Figure 4C). 
However, as minimal disruption of the microbiota community 
was a major aim in developing our inactivated vaccination 
protocol, antibiotic-mediated augmentation of the vaccination 
response was not further employed. While it is beyond the scope 
of the current investigation to determine the exact nature of the 
“transferrable” microbiota that mediates this effect, it will clearly 
be critical to control for microbiota composition in all studies 
employing inactivated oral vaccines.
We next carried out proof-of-principle experiments to deter-
mine whether intestinal responses to peracetic acid-inactivated 
vaccines are functional. To this end, we made use of the murine 
model of invasive non-typhoidal Salmonellosis (36). In this 
model, SOPF mice received high-dose oral streptomycin 24  h 
prior to infection to reduce the density of the microbiota in 
the large intestinal lumen and generate a permissive niche for 
S. Typhimurium growth. 5 ×  105 S. Typhimurium were given 
FigUre 4 | specific iga induction by Pa-sTm is dependent on T cells and the microbiota. (a) TCRβδ−/− and matched heterozygote controls were 
vaccinated three times over 3 weeks with PA-STm. On day 21, after the first vaccination, all mice were euthanized, and IgA in the intestinal lavage analyzed by 
bacterial flow cytometry for Salmonella specific IgA, and ELISA for total IgA concentrations. Pooled data from two independent experiments. Mann–Whitney U test 
P = 0.0079. (B) Female LCM and SPF mice were either co-housed for 3 weeks, or were housed separately under identical conditions. Subsequently, all mice were 
gavaged three times over 3 weeks with PA-STm. Antibody titers were determined as above on day 21 after the initial vaccination. Pooled data from three 
independent experiments. Two-way ANOVA P (hygiene effect) = 0.0142, P (Interaction between housing and hygiene) = 0.0104. (c) C57BL/6 SPF mice were 
pre-treated orally with vehicle only (PBS) or high-dose ampicillin (0.8 g/kg) or gentamycin (1 g/kg) 24 h prior to each PA-STm dose. Three rounds of pre-treatment 
and vaccination were carried out over 3 weeks. On day 21, antibody titers were determined as in (a). Pooled data from two independent experiments. Kruskal–
Wallis P = 0.0140 with Dunn’s post-test.
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orally and grew to a density of 109–1010 CFU per gram intestinal 
content, filling this niche by day 1 post-infection. Once bacteria 
reach a sufficiently high density, virulence factor expression is 
triggered and Salmonella can invade into epithelial cells and 
penetrate to draining lymph nodes and systemic sites (36). This 
is a particularly challenging model for vaccine-mediated protec-
tion as the lethal infectious dose in C57BL/6 mice is <10 CFU. 
Previous work in this model using live-attenuated vaccination 
had demonstrated that O-antigen-specific IgA is a necessary 
component of any observed protection (18). Therefore, we 
additionally tested the effect of PA-STm in antibody-deficient 
animals [JH−/− (38)] and the effect of a vaccine produced from a 
“rough” (i.e., O-antigen-deficient) S. Typhimurium strain SKI10 
(wbaP:aphT) (53). PA-STm vaccinated wild-type mice were com-
pletely protected from an oral challenge of 5 × 105 S. Typhimurium 
in the streptomycin pre-treatment model at 24 h post-infection, 
with no detectable live S. Typhimurium recovered from the 
mLN, despite high levels of cecal colonization (Figures 5A,B). 
Additionally, no cecal pathology was observed in wild-type 
mice vaccinated with PA-STm as determined by histopathology 
(Figure 5C) or fecal Lipocalin 2 (Figure 5D). By contrast, mice 
vaccinated with a peracetic acid-inactivated strain lacking the 
O-antigen (PA-SKI10) showed no protection either at the level 
of cecal pathology or tissue bacterial loads (Figures 5A–D), and 
no IgA binding to wild-type Salmonella (Figure  5E). This was 
not due to reduced antigenicity of this vaccine as IgA induce by 
PA-SKI10 was as good as that induced by PA-STm in binding 
to surface structures of O-sidechain-deficient S. Typhimurium 
mutants (rough or deep-rough strains, Figures 5F,G). Rather, the 
presence of O-sidechains masks most other relevant antigens on 
the surface of live bacteria. As would be predicted from previ-
ous work (18), antibodies were an essential component of the 
protective response, as PA-STm vaccinated JH−/− mice, which 
lack all mature B cells (38), show no measurable protection 
from infection (Figures  5A–E). Furthermore, vaccinated IgA-
deficient mice display greatly reduced protection from infection 
(Figures 5H–J), when compared to IgA heterozygote littermates. 
Therefore, the main protective immune response induced by 
PA-STm was O-antigen-specific IgA.
The sterile nature of PA-STm immediately suggested its 
potential to investigate mucosal immunity in situations of severe 
innate immune deficiency. Both human patients and mice 
carrying mutations in the phagocyte NADPH oxidase com-
ponent gp91phox (cybb) are extremely susceptible to invasive 
Salmonellosis and also develop overt pathology when infected 
with live-attenuated oral vaccination strains (37, 54). In contrast 
to live-attenuated Salmonella, PA-STm was extremely well toler-
ated in cybb-deficient animals with no statistical difference in 
inflammatory scores or intestinal inflammatory markers between 
mock-treated and vaccinated mice (Figure 6A, data not shown).
Additionally, the cybb pathway is not required for successful 
responses to the vaccine, as titers of intestinal IgA (Figure 6B) are 
similar to those of matched wild-type mice. Critically, this adap-
tive immune response is equally protective in cybb-deficient and 
wild-type mice up to 24 h post-infection with a large inoculum 
(5 × 105 CFU, Figures 6C–E), and up to at least 80 h post-infection 
with a small inoculum (50 CFU, Figures 6F–H).
DiscUssiOn
Based on our previous observations with apathogenic species, we 
devised and tested a highly simplified strategy to generate high 
dose inactivated oral vaccines, capable of inducing robust specific 
intestinal IgA responses. The strong oxidizing agent peracetic 
FigUre 5 | Pa-sTm provides protection from non-typhoidal Salmonellosis in an O-antigen and antibody-dependent manner. (a) C57BL/6 SOPF or 
JH−/− mice recently rederived into an SOPF colony were vaccinated once per week for 3 weeks with the indicated vaccine (PA-STm: killed O-antigen-sufficient 
vaccine, PA-SKI10: killed O-antigen-deficient “rough” strain). On day 21, all mice were pre-treated with 1.0 g/kg streptomycin p.o. 24 h later, all mice received 
10 CFU of wild-type S. Typhimurium SB300 p.o. Mice were euthanized 24-h post-infection. (a,B) Live S. Typhimurium CFU in the mesenteric lymph nodes 
(Kruskal–Wallis P = 0.0009, with Dunn’s post-tests) and cecal content. (c) Histopathology of the cecum at 24-h post-infection. (Kruskal–Wallis test P = 0.0325)  
(D) Fecal Lipocalin 2 on day 21 post-vaccination, 24 h post streptomycin treatment and 24 h post-challenge (24 h post-challenge, Kruskal–Wallis P = 0.0006, with 
Dunn’s post-tests). (e–g) Intestinal IgA titer specific for the surface of wild-type S. Typhimurium, rough S. Typhimurium (ΔwbaP) and deep-rough S. Typhimurium 
(ΔrfaI), as determined by bacterial surface-specific bacterial flow cytometry. (h–J) IgA± and IgA−/− SOPF littermate mice were vaccinated three times over 3 weeks 
with PA-STm. All mice were streptomycin pre-treated, followed by infection with 105 CFU wild-type S. Typhimurium. All parameters were assessed 24-h post-
infection. (h) CFU of live S. Typhimurium in the mesenteric lymph nodes (Mann–Whitney U P = 0.0358). (i,J) Intestinal pathology as determined by fecal Lipocalin 2 
levels (Mann–Whitney U P = 0.0357) and histopathology (Mann–Whitney U P = 0.0336).
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FigUre 6 | Oral Pa-sTm is safe for vaccination in cybb-deficient mice and provides dose-dependent protection from tissue invasion and pathology 
up to at least 80-h post-infection in the non-typhoidal Salmonellosis model. C57BL/6 and cybb−/− mice recently re-derived into an identical SOPF foster 
colony were vaccinated three times over 3 weeks with PA-STm or vehicle alone (PBS). (a,B) On day 21 after the first vaccination, cecal pathology was determined 
by fecal Lipocalin 2 ELISA [two-way ANOVA P (genotype) = 0.3583, P (vaccination) = 0.3500, P (Interaction) = 0.3515] (a) and intestinal IgA titers were determined 
by bacterial flow cytometry (Mann–Whitney U test on vaccinated samples only, P = 0.1679) (B). (c–e) Mice vaccinated as in A and B were pre-treated with 1 g/kg 
streptomycin on day 21 after the first vaccination and subsequently infected with 105 wild-type S. Typhimurium. (c) Live S. Typhimurium CFU recovered from the 
mesenteric lymph nodes at 24-h post-infection. (D,e). Intestinal inflammation as determined by fecal Lipocalin 2 (D) and histopathology scoring of cecum tissue  
(e). (c–e) were analyzed by (two-way ANOVA, ***P (vaccination) <0.001) (F–h). Mice vaccinated as in (a,B) were pretreated with 1 g/kg streptomycin on day 21 
after the first vaccination and subsequently infected with 50 CFU wild-type S. Typhimurium. (F,g) Live S. Typhimurium CFU recovered from the mesenteric lymph 
nodes (F) [two-way ANOVA. P (genotype) = <0.0001, P (vaccination) <0.0001, P (interaction) = <0.0001] and spleen (g) (two-way ANOVA. P (genotype) = 0.0098, 
P (vaccination) = 0.0038, P (interaction) = 0.0098) at 80-h post-infection. (h) Intestinal inflammation as determined by fecal Lipocalin 2 up to 80 h (day 3) 
post-infection (two-way repeat-measures ANOVA with Bonferroni post-tests on log-normalized data. **P < 0.01, ****P < 0.0001).
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acid has long been used as a decontaminant in the husbandry 
of axenic animals (55) and in the food industry (56, 57). Here, 
we demonstrate that the bacterial killing efficiency of 0.4% per-
acetic acid is considerably higher than those of standard vaccine 
inactivation protocols (4% paraformaldehyde, pasteurization, 
or 3% hydrogen peroxide), and can be used on a wide range of 
bacterial species. This permits the oral application of very high 
numbers of vaccine particles with close-to-zero risk of inoculat-
ing live bacteria (Figures 1 and 2). When sufficient numbers of 
inactivated bacteria are delivered orally, we can induce a robust 
T-cell-dependent mucosal IgA response against a range of 
Enterobacteriaceae (Figures 3 and 4). This occurs in the complete 
absence of intestinal pathology, in the complete absence of live 
bacteria and in the absence of exogenous mucosal adjuvants 
(Figure 3), even in situations of severe innate immune deficiency 
(Figure 6). The immune responses induced can protect from oral 
infection with virulent S. Typhimurium in the mouse model of 
non-typhoidal Salmonellosis (Figures 5 and 6). This is the first 
demonstration of phagocyte oxidative burst-independent protec-
tion by high-titer IgA in this infectious model. Our observation 
somewhat goes against a prevailing dogma in mouse vaccination 
that sterile material delivered orally induces either tolerance or is 
simply ignored by the immune system (12, 13, 58). While both 
phenomena can be easily observed, our clear demonstration of 
immunity highlights the quantitative nature of mucosal immune 
system stimulation.
The beauty of this strategy is that it permits researchers using 
well-established animal models of host–microbiota interactions 
or host–pathogen–(microbiota) interactions to generate high-
titer IgA responses in an otherwise largely unperturbed host. 
Highly controlled infections or colonizations can then be carried 
out to determine the mechanisms by which IgA alters microbial 
physiology in  vivo (for example, bacterial virulence, induction 
of inflammatory signaling, within-host population dynamics, 
and within-host evolution). When combined with very rigorous 
aseptic technique, this methodology should be safe enough to 
apply in germ-free and gnotobiotic animals without contamina-
tion (55). Extra caution would need to be applied with species 
capable of forming spores, which may be highly resistant (59) 
and hard to detect by in vitro enrichment culture. Another benefit 
of the technique is that the antigenic composition of the vaccine 
is determined by in  vitro growth and the bacterial phenotype 
becomes locked at the time of inactivation. Therefore, there is 
the possibility to grow the vaccination strain under selection to 
maintain phase-locked states, or to overexpress factors associated 
with a high metabolic cost. This is almost impossible to achieve 
with live vaccines due to rapid out-selection of the fittest strains 
in vivo (60). Of note, the more pessimistic reader may spot that 
this is also a potential disadvantage, as bacteria grown in rich 
media in vitro may be antigenically distinct from those in vivo 
and modification of the culture conditions may be important to 
generate appropriate responses.
We envisage this technique as being immediately useful to the 
field of host–microbial interaction in experimental animal models. 
Based on our previous work, we expect the induced IgA responses 
to wane quite rapidly after the final vaccine dose (13) and, there-
fore, the usefulness in human and veterinary medicine may be 
limited. However, it should be noted that two licensed human oral 
vaccines against V. cholera and one vaccine in late-stage clinical 
trials against ETEC (31) work on the basis of high numbers of 
bacteria killed by formalin or heat-treatment (30). All of these 
vaccines include an autologous toxin (or subunit thereof) which 
is a known mucosal adjuvant (61). It remains unclear whether 
the absence of long-term-mucosal memory observed with non-
adjuvanted mucosal vaccines in the murine system is due to 
physiological differences, or the absence of adjuvant. The greatly 
increased efficiency of peracetic acid-mediated inactivation, as 
compared to paraformaldehyde and heat-treatment, suggests that 
this process could be used to increase the efficiency of human oral 
vaccines adjuvented with cholera toxin B or heat-labile toxin B 
subunit. It will additionally be interesting to test these adjuvanted 
vaccines to look for qualitative and quantitative differences in 
activation of mucosal immunity in animal models. Furthermore, 
there are a number of clinical situations where highly susceptible 
patients could benefit from a short-term extremely safe boost 
in mucosal immunity against diverse bacterial strains, such as 
prior to myeloablation, in primary innate immune deficiencies, 
during TNF-blockade, or prior to fecal transplantation. In these 
situations, the ability to easily produce oral vaccines from a broad 
range of bacterial species may be of clinical interest.
Currently, we have not tested whether this technique is also 
suitable for inactivation of strictly anaerobic bacterial species. 
A further limitation is that we have not investigated the nature 
of T cell responses induced by peracetic acid-inactivated oral 
vaccines. Additionally, we observe an effect of microbiota com-
position on the efficiency of specific IgA induction by peracetic 
acid-inactivated vaccines, which suggests that there will be lab-
to-lab variation in absolute efficacy. Despite these caveats, we feel 
this technique finally makes it possible to cleanly study the effects 
of the antibody-mediated intestinal immunity on host-microbial 
interactions.
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